The association between funding by commercial interests and study outcome in randomized controlled drug trials

被引:112
作者
Yaphe, J [1 ]
Edman, R [1 ]
Knishkowy, B [1 ]
Herman, J [1 ]
机构
[1] Hadassah Med Org, Dept Social Med, Kiryat Hayovel Community Hlth Ctr, Family Med Unit, IL-91010 Jerusalem, Israel
关键词
publication bias; randomized controlled trials;
D O I
10.1093/fampra/18.6.565
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. Previous studies limited to specific drugs or journal types have shown an association between the source of funding of research and the published results. Objective. The aim of the present study was to determine the association between source of support of research and published outcomes of randomized controlled drug trials in general interest medical journals. Methods. Randomized controlled drug trials (n = 314) published in five general interest medical journals over a 2-year period were reviewed. Study outcome was classified as positive or negative. Support was classified as pharmaceutical industry or non-industry. Association between source of support and outcome was tested with the chi-squared statistic. Results. Positive findings were found in 77% of studies, negative findings in 20% and an uncertain outcome in 3%. Support from commercial sources was found in 68% of trials. Negative findings were found in 13% of industry-supported studies and in 35% of non-industry-supported studies (chi-squared = 18.36, P < 0.0001, odds ratio = 3.54, 95% confidence interval 1.90-6.62). Conclusions. An association was found between the source of study support and the published outcome. Though the reason for this association cannot be determined from the data collected, future studies may clarify the importance of this finding for readers concerned with the relationship of funding bodies to the publication of research outcomes.
引用
收藏
页码:565 / 568
页数:4
相关论文
共 13 条
  • [1] [Anonymous], 1994, EPI INFO VERSION 6 W
  • [2] The quality of drug studies published in symposium proceedings
    Cho, MK
    Bero, LA
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 124 (05) : 485 - +
  • [3] SOURCE OF FUNDING AND OUTCOME OF CLINICAL-TRIALS
    DAVIDSON, RA
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1986, 1 (03) : 155 - 158
  • [4] PUBLICATION BIAS IN CLINICAL RESEARCH
    EASTERBROOK, PJ
    BERLIN, JA
    GOPALAN, R
    MATTHEWS, DR
    [J]. LANCET, 1991, 337 (8746) : 867 - 872
  • [5] Evaluation of conflict of interest in economic analyses of new drugs used in oncology
    Friedberg, M
    Saffran, B
    Stinson, TJ
    Nelson, W
    Bennett, CL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15): : 1453 - 1457
  • [6] LEXCHIN J, 1995, CAN J CLIN PHARM, V2, P15
  • [7] MCEVOY GK, 1994, AM HOSP FORMULARY SE
  • [8] Reynolds J., 1996, MARTINDALE EXTRA PHA
  • [9] A STUDY OF MANUFACTURER-SUPPORTED TRIALS OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN THE TREATMENT OF ARTHRITIS
    ROCHON, PA
    GURWITZ, JH
    SIMMS, RW
    FORTIN, PR
    FELSON, DT
    MINAKER, KL
    CHALMERS, TC
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (02) : 157 - 163
  • [10] An amnesty for unpublished trials
    Smith, R
    Roberts, I
    [J]. BRITISH MEDICAL JOURNAL, 1997, 315 (7109) : 622 - 622